Next Article in Journal
ALS-Linked P56S-VAPB Mutation Impairs the Formation of Multinuclear Myotube in C2C12 Cells
Next Article in Special Issue
Effect of Factor XIII-A G185T Polymorphism on Visual Prognosis after Photodynamic Therapy for Neovascular Macular Degeneration
Previous Article in Journal
Evaluation and Management of Neurogenic Bladder: What Is New in China?
Previous Article in Special Issue
Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine
Article Menu
Issue 8 (August) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(8), 18601-18627; doi:10.3390/ijms160818601

Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children

1
Institute for Maternal and Child Health (I.R.C.C.S.) Burlo Garofolo, UO Pediatric Hemato-Oncology, Trieste 34137, Italy
2
Department of Life Sciences, University of Trieste, Trieste 34127, Italy
*
Author to whom correspondence should be addressed.
Received: 13 June 2015 / Revised: 21 June 2015 / Accepted: 28 July 2015 / Published: 10 August 2015
(This article belongs to the Special Issue Pharmacogenetics and Personalized Medicine)
View Full-Text   |   Download PDF [777 KB, uploaded 10 August 2015]

Abstract

Hematopoietic stem cell transplantation (HSCT) is an established therapeutic procedure for several congenital and acquired disorders, both malignant and nonmalignant. Despite the great improvements in HSCT clinical practices over the last few decades, complications, such as graft vs. host disease (GVHD) and sinusoidal obstructive syndrome (SOS), are still largely unpredictable and remain the major causes of morbidity and mortality. Both donor and patient genetic background might influence the success of bone marrow transplantation and could at least partially explain the inter-individual variability in HSCT outcome. This review summarizes some of the recent studies on candidate gene polymorphisms in HSCT, with particular reference to pediatric cohorts. The interest is especially focused on pharmacogenetic variants affecting myeloablative and immunosuppressive drugs, although genetic traits involved in SOS susceptibility and transplant-related mortality are also reviewed. View Full-Text
Keywords: hematopoietic stem cell transplantation; pharmacogenetics; graft vs. host disease; sinusoidal obstructive syndrome hematopoietic stem cell transplantation; pharmacogenetics; graft vs. host disease; sinusoidal obstructive syndrome
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Franca, R.; Stocco, G.; Favretto, D.; Giurici, N.; Decorti, G.; Rabusin, M. Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children. Int. J. Mol. Sci. 2015, 16, 18601-18627.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top